BEAUTYFARM MED's stock plummeted 10.62% during intraday trading on Monday, marking a significant downward movement for the healthcare company.
The sharp decline followed the release of the company's 2025 annual results, which showed strong financial performance with revenue increasing 16.7% year-on-year to approximately RMB 3 billion and adjusted net profit surging 41% to about RMB 381 million. Despite these positive figures, investors expressed concerns about whether the company can sustain this profit growth momentum going forward.
Chief Financial Officer Zhou Min addressed these concerns by stating that BEAUTYFARM MED expects to maintain profit growth through organic expansion and strategic acquisitions. The company plans to invest in brand development and digital transformation for 2026, using efficiency gains to fund future growth initiatives.
Comments